Emmaus Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

SELECTED FINANCIAL STATEMENT - ASSETS

SELECTED FINANCIAL STATEMENT - ASSETS

6 Months Ended

Jun. 30, 2024

Balance Sheet Related Disclosures [Abstract]

SELECTED FINANCIAL STATEMENT - ASSETS

NOTE 4 — SELECTED FINANCIAL STATEMENT — ASSETS

Inventories consisted of the following (in thousands):


	June 30, 2024			December 31, 2023
Raw materials and components	$	1,266		$	1,329
Work-in-process		285			186
Finished goods		5,059			5,163
Inventory reserve		(4,982	)		(4,967	)
Total inventories, net	$	1,628		$	1,711

Prepaid expenses and other current assets consisted of the following (in thousands):


	June 30, 2024		December 31, 2023
Prepaid insurance	$	328	$	595
Prepaid expenses		279		536
Other current assets		654		596
Total prepaid expenses and other current assets	$	1,261	$	1,727

Property and equipment consisted of the following (in thousands):


	June 30, 2024			December 31, 2023
Equipment	$	386		$	383
Leasehold improvements		39			39
Furniture and fixtures		99			99
Total property and equipment		524			521
Less: accumulated depreciation		(470	)		(462	)
Total property and equipment, net	$	54		$	59

For the three months ended June 30, 2024 and 2023, depreciation expense was approximately $6,000 and $9,000, respectively. For the six months ended June 30, 2024 and 2023, the depreciation expense was approximately $12,000 and $18,000, respectively.